Sec Form 4 Filing - Pivotal bioVenture Partners Fund I, L.P. @ Evommune, Inc. - 2025-11-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Pivotal bioVenture Partners Fund I, L.P. 2. Issuer Name and Ticker or Trading Symbol Evommune, Inc. [ EVMN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 501 SECOND STREET, SUITE 200 3. Date of Earliest Transaction (MM/DD/YY) 11/07/2025 (Street) SAN FRANCISCO, CA94107 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 11/07/2025 C 1,441,032 A 1,441,032 I See footnotes ( 5 ) ( 10 ) Common Stock 11/07/2025 C 1,632,441 A 1,632,441 I See footnotes ( 6 ) ( 8 ) ( 9 ) Common Stock 11/07/2025 C 294,502 A 294,502 I See footnotes ( 7 ) ( 8 ) ( 9 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series Seed Preferred Stock ( 1 ) 11/07/2025 C 7,145,647 ( 1 ) ( 1 ) Common Stock 838,886 ( 1 ) 0 I See footnotes ( 5 ) ( 10 ) Series Seed Preferred Stock ( 1 ) 11/07/2025 C 3,572,816 ( 1 ) ( 1 ) Common Stock 419,441 ( 1 ) 0 I See footnotes ( 6 ) ( 8 ) ( 9 ) Series A Preferred Stock ( 2 ) 11/07/2025 C 2,582,243 ( 2 ) ( 2 ) Common Stock 324,578 ( 2 ) 0 I See footnotes ( 5 ) ( 10 ) Series A Preferred Stock ( 2 ) 11/07/2025 C 7,230,283 ( 2 ) ( 2 ) Common Stock 908,821 ( 2 ) 0 I See footnotes ( 6 ) ( 8 ) ( 9 ) Series B Preferred Stock ( 3 ) 11/07/2025 C 1,895,260 ( 3 ) ( 3 ) Common Stock 240,756 ( 3 ) 0 I See footnotes ( 5 ) ( 10 ) Series B Preferred Stock ( 3 ) 11/07/2025 C 2,104,740 ( 3 ) ( 3 ) Common Stock 267,367 ( 3 ) 0 I See footnotes ( 6 ) ( 8 ) ( 9 ) Series C Preferred Stock ( 4 ) 11/07/2025 C 313,571 ( 4 ) ( 4 ) Common Stock 36,812 ( 4 ) 0 I See footnotes ( 5 ) ( 10 ) Series C Preferred Stock ( 4 ) 11/07/2025 C 313,571 ( 4 ) ( 4 ) Common Stock 36,812 ( 4 ) 0 I See footnotes ( 6 ) ( 8 ) ( 9 ) Series C Preferred Stock ( 4 ) 11/07/2025 C 2,508,575 ( 4 ) ( 4 ) Common Stock 294,502 ( 4 ) 0 I See footnotes ( 7 ) ( 8 ) ( 9 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Pivotal bioVenture Partners Fund I, L.P. 501 SECOND STREET, SUITE 200 SAN FRANCISCO, CA94107 X X Pivotal bioVenture Partners Fund I G.P., L.P. 501 SECOND STREET, SUITE 200 SAN FRANCISCO, CA94107 X X Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 SECOND STREET, SUITE 200 SAN FRANCISCO, CA94107 X X Signatures /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner 11/12/2025 Signature of Reporting Person Date /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I G.P., L.P., By: Robert Hopfner, Managing Partner 11/12/2025 Signature of Reporting Person Date /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I U.G.P. Ltd., By: Robert Hopfner, Managing Partner 11/12/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date. ( 2 )Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date. ( 3 )Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. ( 4 )Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. ( 5 )Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL"). ( 6 )Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). ( 7 )Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). ( 8 )The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. ( 9 )The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein. ( 10 )The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.